Evidence map›Paper›PMID 35474967›Full record

ArticleCell reports methods2022

Biosensor for deconvolution of individual cell fate in response to ion beam irradiation.

Martin Niklas, Julian Schlegel, Hans Liew, Ferdinand Zimmermann, Katrin Rein, Dietrich W M Walsh, Oleh Dzyubachyk, Tim Holland-Letz, Shirin Rahmanian, Steffen Greilich and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports methods, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Biosensor Cell-Fit-HDSTAR protocols · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Martin NiklasDivision of Molecular and Translational Radiation Oncology and Clinical Cooperation Unit Translational Radiation Oncology, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, 69120 Heidelberg, Germany.
Julian SchlegelDivision of Molecular and Translational Radiation Oncology and Clinical Cooperation Unit Translational Radiation Oncology, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, 69120 Heidelberg, Germany.
Hans LiewDivision of Molecular and Translational Radiation Oncology and Clinical Cooperation Unit Translational Radiation Oncology, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, 69120 Heidelberg, Germany.
Ferdinand ZimmermannDivision of Molecular and Translational Radiation Oncology and Clinical Cooperation Unit Translational Radiation Oncology, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, 69120 Heidelberg, Germany.
Katrin ReinDivision of Molecular and Translational Radiation Oncology and Clinical Cooperation Unit Translational Radiation Oncology, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, 69120 Heidelberg, Germany.
Dietrich W M WalshDivision of Molecular and Translational Radiation Oncology and Clinical Cooperation Unit Translational Radiation Oncology, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, 69120 Heidelberg, Germany.
Oleh DzyubachykDepartment of Radiology and Department of Cell and Chemical Biology, Leiden University Medical Center, 2333 ZC Leiden, the Netherlands.
Tim Holland-LetzDivision of Biostatistics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Shirin RahmanianDivision of Medical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Steffen GreilichDivision of Medical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Armin RunzDivision of Medical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Oliver JäkelNational Center for Tumor Diseases, German Cancer Consortium, Heidelberg Institute of Radiation Oncology and National Center for Radiation Oncology, 69120 Heidelberg, Germany.
Jürgen DebusDivision of Molecular and Translational Radiation Oncology and Clinical Cooperation Unit Translational Radiation Oncology, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, 69120 Heidelberg, Germany.
Amir AbdollahiDivision of Molecular and Translational Radiation Oncology and Clinical Cooperation Unit Translational Radiation Oncology, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, 69120 Heidelberg, Germany.
German Cancer Research Center · DELeiden University Medical Center · NL

Funding

Translational Studies in FLASH Particle RadiotherapyP01CA257904 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Mary E. Putt · 2022 to 2026
$14.2M
NCI NIH HHS P01 CA257904
6 · The paper itself

Abstract

Clonogenic survival assay constitutes the gold standard method for quantifying radiobiological effects. However, it neglects cellular radiation response variability and heterogeneous energy deposition by ion beams on the microscopic scale. We introduce "Cell-Fit-HD

Indexed as

Biosensing TechniquesHeavy Ion RadiotherapyRadiometrybiodosimetrybiosensorCell-Fit-HDclinical ion beam irradiationdouble strand breaksfluorescent nuclear track detectorFNTDion beam cancer therapyparticle therapyradiobiological effects

Identifiers

PMID35474967
PMCPMC9017136
OpenAlexW4213226443

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.